Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Daily dose of aspirin may reduce prostate cancer risk: US Study

A US study has found that a daily dose of aspirin may reduce the risk of prostate cancer, but Cancer Research UK has noted that regular use of aspirin can cause serious side-effects and should not be undertaken unless recommended by a doctor.Several previous studies have looked at the possibility of an association between aspirin use and a reduced risk of prostate cancer.In the latest study, scientists at the Fred Hutchinson Cancer Research Centre in Seattle, led by Dr Janet Stanford, looked at data on 1,001 prostate cancer patients and a similar number of cancer-free volunteers.

16 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

K-State researcher receives grant from NIH to continue cancer research

Understanding how cancer cells communicate with each other and how to enhance their receptiveness to drug treatments is the focus of promising work by a Kansas State University researcher.Annelise Nguyen, assistant professor of toxicology in the department of diagnostic medicine and pathobiology at K-State's College of Veterinary Medicine, recently received a $370,000 grant from the National Institutes of Health to continue her cancer research.

12 Aug 2010

Augmenix announces commercial implantation of SpaceOAR absorbable spacer system for radiation treatment

Augmenix, Inc. announced today that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company's CE Mark approved SpaceOAR System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues.

12 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

Study examines link between breath, cancer detection

A test using a patient's breath could be developed to detect lung, breast, bowel and prostate cancers, a team of scientists have discovered. While these results are only preliminary, the study1 published in the British Journal of Cancer today (Wednesday), found that sensors could distinguish between the breath of healthy patients and those who have cancer.

11 Aug 2010

GenSpera issued additional patent for G-202

GenSpera, Inc. announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office as US Patent 7,767,648. The patent covers the method of use for G-202, GenSpera's lead oncology drug, which is currently in a Phase I clinical study treating cancer patients whose disease has progressed after other treatments.

11 Aug 2010

Magnetic resonance image analysis helps assessment of prostate cancer severity

Rutgers researchers are developing methods that can accurately assess the severity of prostate cancer by analyzing magnetic resonance images and spectra of a patient's prostate gland. This may help physicians decide more confidently which patients need aggressive treatment and which are better served by "watchful waiting," and could even postpone or eliminate invasive biopsies in patients with low-grade tumors.

11 Aug 2010

Study shows physicians reluctant to use finasteride for prostate cancer

Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

11 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

Breath test to detect cancer: Study

According to researchers cancer may soon be detectable using a breath test. They are now developing sensors that can detect chemical markers of lung, breast, bowel and prostate cancer in a person's breath. The new portable device has been purported as an “electronic nose” that can detect early cancers. As a cancer grows, the surface of the cells emits chemicals. The research found that sensors – involving gold nanoparticles – could be used to detect these chemicals in the breath.

10 Aug 2010

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation, Inc. today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Scientists discover role of Mnk enzyme in prostate cancer development

A kinase is a type of enzyme the body uses to regulate the functions of the proteins required for cell growth and maintenance, and researchers have discovered that one in particular plays a key role in developing prostate cancer. "It's known as Mnk, and although it appears not to be essential for normal cell maintenance, it's important for cancer growth" said Dr. Luc Furic, a postdoctoral researcher working with Dr. Nahum Sonenberg at McGill University's Goodman Cancer Research Centre and Department of Biochemistry.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New T cell engineering approach can improve success rate of immune-cell therapies

Daily dose of aspirin may reduce prostate cancer risk: US Study

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

K-State researcher receives grant from NIH to continue cancer research

Augmenix announces commercial implantation of SpaceOAR absorbable spacer system for radiation treatment

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Study examines link between breath, cancer detection

GenSpera issued additional patent for G-202

Magnetic resonance image analysis helps assessment of prostate cancer severity

Study shows physicians reluctant to use finasteride for prostate cancer

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Breath test to detect cancer: Study

Theragenics reports consolidated revenue of $20.8M for second-quarter 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Synta second-quarter net loss increases to $9.1 million

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Scientists discover role of Mnk enzyme in prostate cancer development

Isis second-quarter pro forma net operating loss increases to $15.5 million

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in